| Name (Synonyms) | Correlation | |
|---|---|---|
| drug896 | Digital intervention Wiki | 1.00 |
| drug1413 | Information-only intervention Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001248 | Asthenopia NIH | 1.00 |
| D013180 | Sprains and Strains NIH | 0.71 |
| D001008 | Anxiety Disorders NIH | 0.15 |
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Description: mortality rates in two groups will be compared
Measure: mortality Time: 4 months